CD8A and neoplasm: Overall, these data support the selective inhibition of Notch1 to both bypass the gastrointestinal side effects and global immunosuppression associated with pan-Notch inhibition and most importantly, to maintain an anti-tumor CD8+ T cell population needed to kill the tumor cells.